StreetInsider.com Pre-Open Movers 12/26
StreetInsider.com Pre-Open Movers:
Telik (Nasdaq: TELK) 72% LOWER; Announced negative results from three separate Phase 3 clinical trials of its investigational drug TELCYTA. ASSIST-1 and ASSIST-2 Trials Did Not Achieve its Primary Endpoint, ASSIST-3 Compromised.
ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) 15% HIGHER; its Investigational New Drug (IND) application for the clinical development of its proprietary cancer drug ANX-530 has been accepted by the FDA. In taking this action, the FDA acknowledged the suitability of the Company's clinical study protocol to establish the bioequivalence of ANX-530, and Navelbine. Navelbine is an anti-cancer agent approved for use in non-small cell lung cancer.
Fuwei Films Co., Ltd. (Nasdaq: FFHL) 13% HIGHER; last week's IPO extends gains
EpiCept Corporation (Nasdaq: EPCT) 10% HIGHER; entered into a license agreement with DURECT Corporation (Nasdaq: DRRX) pursuant to which it has granted DURECT the exclusive, worldwide rights to certain of EpiCept's intellectual property for a transdermal patch containing bupivacaine for the treatment of back pain.
Taylor Devices Inc. (Nasdaq: TAYD) 6% HIGHER; Taiwan earthquake, tsunami
InterMune Inc. (Nasdaq: ITMN) 5% HIGHER; continues Friday's 29% move. Wachovia and Leerink Swann upgrades
Escala Group Inc. (Nasdaq: ESCL) 4% LOWER; continues to give back last week's gains.
Mamma.com Inc. (Nasdaq: MAMA) 1.5% LOWER; continues to give back last few weeks of gains.
CPAC, Inc. (NASDAQ: CPAK) INDICATED HIGHER; entered into a definitive merger agreement under which affiliates of Buckingham Capital Partners II, L.P. will acquire all the outstanding shares of CPAC, Inc., for approximately $42.8 million, plus the assumption of approximately $6.7 million in debt. Under the terms of the merger agreement, CPAC shareholders will receive $8.65 in cash for each share of CPAC common stock they hold.
Create E-mail AlertRelated Categories
General NewsSpecial Reports
Stocks Mentioned
+0.00
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
